Bone Biologics (BBLG) Fundamental Analysis: Revenue, Earnings & Valuation

0.81 / 10

Underperform

Fundamentals are subpar, overall 0.8/10. Profit‑MV is a relative strength, yet Revenue‑MV, Cash‑MV, Asset‑MV and ROA are negative, indicating weak earnings, cash and asset efficiency.

Analysis Checks(1/10)

Revenue-MV

Value-0.11

Score0/3

Weight14.38%

1M Return-4.18%

ROA (%)

Value-64.39

Score0/3

Weight15.88%

1M Return-6.58%

Net cash flow from operating activities / Operating revenue (%)

Value-982.50

Score0/3

Weight15.92%

1M Return-6.63%

Profit-MV

Value0.66

Score2/3

Weight-13.58%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-64.39

Score0/3

Weight15.88%

1M Return-6.58%

EBIT / Total operating revenue (%)

Value-1049.47

Score0/3

Weight15.92%

1M Return-5.19%

Asset-MV

Value-0.55

Score1/3

Weight-1.45%

1M Return0.38%

Net profit / Total operating revenue (%)

Value-654.10

Score0/3

Weight16.21%

1M Return-6.68%

Cash-MV

Value0.02

Score1/3

Weight12.87%

1M Return-4.16%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight7.95%

1M Return-2.39%

Is BBLG fundamentally strong?

BBLG scores 0.81/10 on fundamentals and holds a Premium valuation at present. Backed by its -70.17% ROE, 0.00% net margin, -0.72 P/E ratio, 0.41 P/B ratio, and 90.85% earnings growth, these metrics solidify its Underperform investment rating.